Antisense Oligonucleotide Treatment for a Pseudoexon-Generating Mutation in the NPC1 Gene Causing Niemann-Pick Type C

被引:38
作者
Rodriguez-Pascau, Laura [1 ,2 ,3 ]
Coll, Maria Josep [2 ,4 ]
Vilageliu, Lluisa [1 ,2 ,3 ]
Grinberg, Daniel [1 ,2 ,3 ]
机构
[1] Univ Barcelona, Fac Biol, Dept Genet, Barcelona, Spain
[2] CIBERER, Barcelona, Spain
[3] Univ Barcelona, Inst Biomed, Barcelona, Spain
[4] Corp Sanitaria Clin, Hosp Clin, Inst Bioquim Clin, Barcelona, Spain
关键词
Pseudoexon-generating mutation; Niemann-Pick type C disease; NPC1; gene; morpholino treatment; DISEASE TYPE-C; PROTEIN; IDENTIFICATION; PHENOTYPE; TRAFFICKING; DOMAIN;
D O I
10.1002/humu.21119
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Niemann-Pick type C disease is an autosomal recessive disorder caused by mutations in either the NPC1 or NPC2 gene. While most of the mutations are missense, a few splicing mutations have also been described. We identified and characterized a novel point mutation c.1554-1009G>A located in intron 9 of the NPC1 gene in a Spanish patient. Sequencing of the cDNA from the patient showed that this intronic mutation creates a cryptic donor splice site resulting in the incorporation of 194 bp of intron 9 as a new exon (pseudoexon) in the mRNA. This new transcript bears a premature termination codon and is degraded by the nonsense-mediated mRNA decay mechanism. Experimental confirmation that the point mutation generates the inclusion of a pseudoexon in the mRNA was obtained using a minigene. A specific antisense morpholino oligonucleotide targeted to the cryptic splice site was designed and transfected into fibroblasts from the patient. Using this approach, normal splicing was restored. These results demonstrate the importance of screening deep intronic regions and support the efficacy of antisense therapeutics for the treatment of diseases caused by pseudoexon-generating mutations. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:E993 / E1001
页数:9
相关论文
共 28 条
[1]   Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation [J].
Aouadi, Myriam ;
Tesz, Gregory J. ;
Nicoloro, Sarah M. ;
Wang, Mengxi ;
Chouinard, My ;
Soto, Ernesto ;
Ostroff, Gary R. ;
Czech, Michael P. .
NATURE, 2009, 458 (7242) :1180-U116
[2]   Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis [J].
Carstea, ED ;
Morris, JA ;
Coleman, KG ;
Loftus, SK ;
Zhang, D ;
Cummings, C ;
Gu, J ;
Rosenfeld, MA ;
Pavan, WJ ;
Krizman, DB ;
Nagle, J ;
Polymeropoulos, MH ;
Sturley, SL ;
Ioannou, YA ;
Higgins, ME ;
Comly, M ;
Cooney, A ;
Brown, A ;
Kaneski, CR ;
BlanchetteMackie, EJ ;
Dwyer, NK ;
Neufeld, EB ;
Chang, TY ;
Liscum, L ;
Strauss, JF ;
Ohno, K ;
Zeigler, M ;
Carmi, R ;
Sokol, J ;
Markie, D ;
ONeill, RR ;
vanDiggelen, OP ;
Elleder, M ;
Patterson, MC ;
Brady, RO ;
Vanier, MT ;
Pentchev, PG ;
Tagle, DA .
SCIENCE, 1997, 277 (5323) :228-231
[3]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[4]   A Deep Intronic Mutation in FGB Creates a Consensus Exonic Splicing Enhancer Motif That Results in Afibrinogenemia Caused by Aberrant mRNA Splicing, Which Can Be Corrected In Vitro With Antisense Oligonucleotide Treatment [J].
Davis, Ryan L. ;
Homer, Vivienne M. ;
George, Peter M. ;
Brennan, Stephen O. .
HUMAN MUTATION, 2009, 30 (02) :221-227
[5]  
Di Leo Enza, 2004, Hum Mutat, V24, P440, DOI 10.1002/humu.9287
[6]   Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C patients: genotype-phenotype correlations [J].
Fernandez-Valero, EM ;
Ballart, A ;
Iturriaga, C ;
Lluch, M ;
Macias, J ;
Vanier, MT ;
Pineda, M ;
Coll, MJ .
CLINICAL GENETICS, 2005, 68 (03) :245-254
[7]   Structure of a cholesterol-binding protein deficient in Niemann-Pick type C2 disease [J].
Friedland, N ;
Liou, HL ;
Lobel, P ;
Stock, AM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2512-2517
[8]   Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides [J].
Friedman, KJ ;
Kole, J ;
Cohn, JA ;
Knowles, MR ;
Silverman, LM ;
Kole, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (51) :36193-36199
[9]   An FBN1 pseudoexon mutation in a patient with Marfan syndrome: confirmation of cryptic mutations leading to disease [J].
Guo, Dong-chuan ;
Gupta, Prateek ;
Tran-Fadulu, Van ;
Guidry, Tera V. ;
Leduc, Magalie S. ;
Schaefer, Frederick V. ;
Milewicz, Dianna M. .
JOURNAL OF HUMAN GENETICS, 2008, 53 (11-12) :1007-1011
[10]   DMD pseudoexon mutations:: Splicing efficiency, phenotype, and potential therapy [J].
Gurvich, Olga L. ;
Tuohy, Therese M. ;
Howard, Michael T. ;
Finkel, Richard S. ;
Medne, Livija ;
Anderson, Christine B. ;
Weiss, Robert B. ;
Wilton, Steve D. ;
Flanigan, Kevin M. .
ANNALS OF NEUROLOGY, 2008, 63 (01) :81-89